The First Affiliated Hospital of Naval Medical University
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- After treatment, whether the response rate of patients using the Vibrabot vibrating capsules alone reaches 50%.
研究概览
简要总结
This study is a multi-center prospective cohort study, which plans to include 300 patients with chronic functional constipation to treat with Vibrabot capsules, and at the same time, include ≥300 patients receiving constipation treatment during the same period.
During the study, it is necessary to collect the patients' basic information, baseline constipation status and treatment information, capsule intake during treatment, and concomitant medication. During the treatment phase, patients follow the doctor's advice to receive Vibrabot capsule treatment and maintain stable dietary intake and exercise according to the constipation diagnosis and treatment guidelines.
During the study, patients need to scan the two-dimensional code or search for the electronic questionnaire "Vibrabot Health" Official Account on WeChat, and fill in the relevant information during the treatment in the electronic questionnaire in a timely and truthful manner. The treatment effect of the patients is evaluated by assessing the number of occurrences of spontaneous bowel movements (SBM) and complete spontaneous bowel movements (CSBM).
详细描述
Constipation is characterized by a decrease in bowel movements, dry and hard stools, and difficulty in defecation. With changes in diet, faster pace of life, and social psychological factors, the prevalence of chronic constipation is on the rise. The global incidence of chronic constipation is 14%, while the prevalence of chronic constipation in adults in China is 4.0% to 10.0%. The prevalence of functional constipation in China is 6%. The high-risk groups for constipation include the elderly, women, diabetics, those taking opiates, antipsychotic drugs, or bedridden patients. Occupation, lifestyle, dietary habits, mental health, family history of constipation, and BMI are factors related to constipation.
Constipation affects patients' quality of life, and some patients abuse laxatives or repeatedly seek medical treatment, increasing medical costs. The main treatments for constipation are adjusting lifestyle, medication, psychotherapy, biofeedback, and surgery. However, these methods often have side effects, and patient satisfaction is still relatively low. A new approach needs to be explored to address this clinical problem.
The Disposable Gastrointestinal Vibrating Capsule System (Vibrabot capsule) (NMPA Device Approval No. 20223090282) is the world's first approved and marketed product for treating constipation through purely physical means. It can provide intermittent comfortable massages to the digestive tract, activate the intestinal neural network, awaken intestinal motility, and help alleviate constipation issues. Clinical study results show that the product is safe to use and can increase the frequency of bowel movements in patients with chronic functional constipation.
This study focuses on post-marketing clinical study for patients with functional constipation of varying severity, further evaluating the efficacy of the product in a large sample population.
Through this real-world study, to analyze the response of functional constipation patients with different severity, treatment status, capsule dosage, and combined medication to Vibrabot capsule, as well as the duration of efficacy maintenance during the follow-up period; to compare the efficacy with patients treated with drugs or other therapies during the same period, explore the possibility of curing functional constipation patients, further improve the treatment satisfaction of constipation patients, and promote the establishment and application of consensus or guidelines for the use of Vibrabot capsule in treating functional constipation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who can be diagnosed with functional constipation according to the Rome IV criteria.
- •Patients who consent to participate in this trial and voluntarily sign the informed consent form (ICF).
排除标准
- •People who are not eligible for surgery or refuse to undergo any abdominal surgery;
- •People with known or suspected gastrointestinal obstruction, stenosis, diverticulum, bleeding, malformation, and fistula.
- •People allergic to polymeric materials;
- •People implanted with cardiac pacemakers and using gastrointestinal pacemakers;
- •People with abdominal aortic aneurysms, gastrointestinal vascular lesions, ulcers, and lesions with bleeding tendencies.
- •People with dysphagia;
- •Pregnant women;
- •People with severe depression and anxiety and severe acute gastrointestinal lesions.
- •People with other conditions, so the investigator considers them not eligible for this study.
结局指标
主要结局
After treatment, whether the response rate of patients using the Vibrabot vibrating capsules alone reaches 50%.
时间窗: At the end of the sixth week of treatment
The definition of the responder is a patient with an average weekly increase of ≥1 complete spontaneous bowel movement (CSBM) compared to the baseline.
次要结局
- Proportion of patients with an average increase of ≥1 CSBMs per week compared to the baseline period(At the end of the sixth week of treatment)
- Proportion of patients with an average increase of ≥1 CSBMs per week during the follow-up phase compared to the baseline period;(At the end of the sixth week of treatment)
- Proportion of subjects with ≥3 SBMs per week and an increase of ≥1 CSBMs during at least 4 weeks of treatment compared to baseline(At the end of the sixth week of treatment)
- Proportion of respondents with an average of ≥3 SBMs per week during the treatment period(At the end of the sixth week of treatment)
- Time of first use of laxative or enema after a course of vibrating capsule treatment (6 weeks)(After the end of the sixth week of treatment)
- Proportion of constipated patients who use/do not use other constipation treatment methods(at the end of the 4-week follow-up)
- Proportion of patients with a reduction of ≥1 point in total Patient Assessment of Constipation Symptom (PAC-SYM) scores after treatment compared to the baseline period(At the end of the sixth week of treatment)
- Proportion of patients with an average of ≥3 SBMs per week during the follow-up phase(at the end of the 4-week follow-up)
- Proportion of patients with a reduction of ≥1 point in total Patient Assessment of Constipation Quality of Life questionnaire(PAC-QOL) scores after treatment compared to the baseline period(At the end of the sixth week of treatment)